NASDAQ:GMTX

Gemini Therapeutics News Headlines

$10.68
-0.54 (-4.81 %)
(As of 04/20/2021 11:40 AM ET)
Add
Compare
Today's Range
$10.68
Now: $10.68▼
$10.99
50-Day Range
$11.01
MA: $14.62▼
$18.00
52-Week Range
$10.57
Now: $10.68▼
$19.08
Volume1,125 shs
Average Volume285,474 shs
Market Capitalization$459.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Gemini Therapeutics (NASDAQ GMTX) News Headlines Today

SourceHeadline
-$0.32 Earnings Per Share Expected for Gemini Therapeutics, Inc. (NASDAQ:GMTX) This Quarter-$0.32 Earnings Per Share Expected for Gemini Therapeutics, Inc. (NASDAQ:GMTX) This Quarter
americanbankingnews.com - April 17 at 4:10 AM
Gemini Therapeutics (NASDAQ:GMTX) Shares Gap Down to $11.77Gemini Therapeutics (NASDAQ:GMTX) Shares Gap Down to $11.77
americanbankingnews.com - April 14 at 11:58 AM
Gemini Therapeutics (NASDAQ:GMTX) Now Covered by Analysts at SVB LeerinkGemini Therapeutics (NASDAQ:GMTX) Now Covered by Analysts at SVB Leerink
americanbankingnews.com - April 14 at 8:58 AM
Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 13 at 8:12 AM
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical OfficerGemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
finance.yahoo.com - April 12 at 9:23 AM
Brokers Set Expectations for Gemini Therapeutics, Inc.s Q1 2021 Earnings (NASDAQ:GMTX)Brokers Set Expectations for Gemini Therapeutics, Inc.'s Q1 2021 Earnings (NASDAQ:GMTX)
americanbankingnews.com - April 12 at 1:26 AM
Gemini Therapeutics (NASDAQ:GMTX) Trading Down 5.9%Gemini Therapeutics (NASDAQ:GMTX) Trading Down 5.9%
americanbankingnews.com - April 9 at 3:18 PM
Gemini Therapeutics (NASDAQ:GMTX) Shares Gap Up to $13.52Gemini Therapeutics (NASDAQ:GMTX) Shares Gap Up to $13.52
americanbankingnews.com - April 8 at 10:44 AM
Gemini Therapeutics (NASDAQ:GMTX) Earns Outperform Rating from Analysts at SVB LeerinkGemini Therapeutics (NASDAQ:GMTX) Earns Outperform Rating from Analysts at SVB Leerink
americanbankingnews.com - April 8 at 7:58 AM
Gemini Therapeutics (NASDAQ:GMTX) Trading 4.4% Higher Gemini Therapeutics (NASDAQ:GMTX) Trading 4.4% Higher
americanbankingnews.com - April 7 at 1:32 PM
FS Development Corp. (NASDAQ:GMTX) Expected to Post Q1 2021 Earnings of ($0.32) Per ShareFS Development Corp. (NASDAQ:GMTX) Expected to Post Q1 2021 Earnings of ($0.32) Per Share
americanbankingnews.com - April 1 at 8:06 AM
Why does Australia need a Women’s Economic Security Minister?Why does Australia need a Women’s Economic Security Minister?
au.finance.yahoo.com - March 31 at 10:39 AM
AIAG Announces 4,000th Member CompanyAIAG Announces 4,000th Member Company
sg.finance.yahoo.com - March 31 at 10:39 AM
FS Development (NASDAQ:GMTX) Stock Price Down 1.9%FS Development (NASDAQ:GMTX) Stock Price Down 1.9%
americanbankingnews.com - March 31 at 12:26 AM
Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business UpdateGemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 29 at 7:01 PM
GMTX.OQ - Gemini Therapeutics Inc Profile | ReutersGMTX.OQ - Gemini Therapeutics Inc Profile | Reuters
reuters.com - March 4 at 7:52 PM
Gemini Therapeutics IncGemini Therapeutics Inc
reuters.com - March 2 at 1:02 PM
Forsite Capitals third SPAC Foresite Life Sciences files for a $250 million IPOForsite Capital's third SPAC Foresite Life Sciences files for a $250 million IPO
nasdaq.com - February 26 at 8:37 PM
Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare ConferenceGemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 19 at 8:18 AM
Foresite Capitals SPAC FS Development II prices further upsized $175 million IPOForesite Capital's SPAC FS Development II prices further upsized $175 million IPO
nasdaq.com - February 17 at 8:34 AM
Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic VariantsGemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants
finance.yahoo.com - February 17 at 8:34 AM
This page was last updated on 4/20/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.